Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.
Cottu P, Cheeseman S, Hall P, Wöckel A, Scholz CW, Bria E, Orlandi A, Ribelles N, Vallet M, Niklas N, Hogg C, Aggarwal S, Moreira J, Lucerna M, Collin SM, Logue A, Long GH. Cottu P, et al. Among authors: ribelles n. Breast Cancer Res Treat. 2024 Oct 20. doi: 10.1007/s10549-024-07506-4. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39427280
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Free PMC article. Clinical Trial.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Pérez-García JM, Cortés J, Ruiz-Borrego M, Colleoni M, Stradella A, Bermejo B, Dalenc F, Escrivá-de-Romaní S, Calvo Martínez L, Ribelles N, Marmé F, Cortés A, Albacar C, Gebhart G, Prat A, Kerrou K, Schmid P, Braga S, Di Cosimo S, Gion M, Antonarelli G, Popa C, Szostak E, Alcalá-López D, Gener P, Rodríguez-Morató J, Mina L, Sampayo-Cordero M, Llombart-Cussac A; PHERGain Trial Investigators. Pérez-García JM, et al. Among authors: ribelles n. Lancet. 2024 Apr 27;403(10437):1649-1659. doi: 10.1016/S0140-6736(24)00054-0. Epub 2024 Apr 3. Lancet. 2024. PMID: 38582092 Clinical Trial.
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
Gebhart G, Keyaerts M, Guiot T, Flamen P, Ruiz-Borrego M, Stradella A, Bermejo B, Escriva-de-Romani S, Calvo Martínez L, Ribelles N, Fernandez-Abad M, Albacar C, Colleoni M, Garrigos L, Atienza de Frutos M, Dalenc F, Prat A, Marmé F, Schmid P, Kerrou K, Braga S, Gener P, Sampayo-Cordero M, Cortés J, Pérez-García JM, Llombart-Cussac A. Gebhart G, et al. Among authors: ribelles n. J Nucl Med. 2024 May 1;65(5):708-713. doi: 10.2967/jnumed.123.266384. J Nucl Med. 2024. PMID: 38575192
Named entity recognition for de-identifying Spanish electronic health records.
Moreno-Barea FJ, López-García G, Mesa H, Ribelles N, Alba E, Jerez JM, Veredas FJ. Moreno-Barea FJ, et al. Among authors: ribelles n. Comput Biol Med. 2024 Dec 21;185:109576. doi: 10.1016/j.compbiomed.2024.109576. Online ahead of print. Comput Biol Med. 2024. PMID: 39709869 Free article.
Validation of the Upper Limb Functional Index on Breast Cancer Survivor.
Martín-Martín J, Pajares-Hachero B, Alba-Conejo E, Ribelles N, Cuesta-Vargas AI, Roldán-Jiménez C. Martín-Martín J, et al. Among authors: ribelles n. Int J Environ Res Public Health. 2023 Mar 12;20(6):4997. doi: 10.3390/ijerph20064997. Int J Environ Res Public Health. 2023. PMID: 36981904 Free PMC article.
Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study.
Ribelles N, Pascual J, Galvez-Carvajal L, Ruiz-Medina S, Garcia-Corbacho J, Benitez JC, Dominguez-Recio ME, Torres E, Oliva L, Zalabardo M, Rueda A, Alba E. Ribelles N, et al. JCO Glob Oncol. 2024 Mar;10:e2300363. doi: 10.1200/GO.23.00363. JCO Glob Oncol. 2024. PMID: 38513186 Free PMC article.
ESMO Guidance for Reporting Oncology real-World evidence (GROW).
Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, Dellaporta T, Vogel A, Prelaj A, Groenwold RHH, Martins H, Stahel R, Bliss J, Kather J, Ribelles N, Perrone F, Hall PS, Dienstmann R, Booth CM, Pentheroudakis G, Delaloge S, Koopman M. Castelo-Branco L, et al. Among authors: ribelles n. Ann Oncol. 2023 Dec;34(12):1097-1112. doi: 10.1016/j.annonc.2023.10.001. Epub 2023 Oct 15. Ann Oncol. 2023. PMID: 37848160 Free article. No abstract available.
Correction to: SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022).
Garcia-Saenz JA, Blancas I, Echavarria I, Hinojo C, Margeli M, Moreno F, Pernas S, Ramon Y Cajal T, Ribelles N, Bellet M. Garcia-Saenz JA, et al. Among authors: ribelles n. Clin Transl Oncol. 2023 Sep;25(9):2759. doi: 10.1007/s12094-023-03229-y. Clin Transl Oncol. 2023. PMID: 37273149 Free PMC article. No abstract available.
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (2022).
Garcia-Saenz JA, Blancas I, Echavarria I, Hinojo C, Margeli M, Moreno F, Pernas S, Ramon Y Cajal T, Ribelles N, Bellet M. Garcia-Saenz JA, et al. Among authors: ribelles n. Clin Transl Oncol. 2023 Sep;25(9):2665-2678. doi: 10.1007/s12094-023-03203-8. Epub 2023 May 6. Clin Transl Oncol. 2023. PMID: 37148499 Free PMC article.
87 results